Alkermes (ALKS) Stock Forecast & Price Target

Compare

583 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALKS Analyst Ratings

Moderate Buy

11 Buy

5 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Alkermes

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$44.50

▲(53.98% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $44.50 with a high forecast of $58.00 and a low forecast of $34.00. The average price target represents a 53.98% change from the last price of $28.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","42":"$42","59":"$59","33.5":"$33.5","50.5":"$50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,33.5,42,50.5,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.7,32.8,34.9,37,39.1,41.2,43.3,45.4,47.5,49.6,51.7,53.8,55.900000000000006,{"y":58,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.7,31.76153846153846,32.823076923076925,33.88461538461539,34.94615384615385,36.00769230769231,37.06923076923077,38.13076923076923,39.19230769230769,40.253846153846155,41.315384615384616,42.37692307692308,43.43846153846154,{"y":44.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.7,30.953846153846154,31.20769230769231,31.46153846153846,31.715384615384615,31.96923076923077,32.223076923076924,32.47692307692308,32.73076923076923,32.98461538461538,33.238461538461536,33.49230769230769,33.746153846153845,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$58.00

Average Price Target$44.50

Lowest Price Target$34.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Douglas Tsao

H.C. Wainwright

$46

Hold

59.17%

Upside

Reiterated

11/20/25

Cautious Optimism: Alkermes' Strategic Moves and Market Potential Amidst Investor ConcernsValuation and Risks. Our Neutral rating and price target of $46 are based on 7.4x our 2035 discounted risk-adjusted revenue estimate of $1B. We adjust each pipeline asset for the probability of success (PoS). All commercial asset revenues are assigned a PoS of 100%. We assign a for ALKS 2680 as a Phase 2 asset. We assume a 17% tax rate. Risks include clinical development, regulatory approval, and commercial execution.

Leonid Timashev

RBC Capital

$47

Buy

62.63%

Upside

Reiterated

11/19/25

Analysts Are Bullish on These Healthcare Stocks: Alkermes (ALKS), Medtronic (MDT)

Joon Lee

Truist Financial

$50→$55

Buy

90.31%

Upside

Reiterated

11/17/25

Truist Financial Keeps Their Buy Rating on Alkermes (ALKS)

Akash Tewari

Jefferies

$58

Buy

100.69%

Upside

Reiterated

11/13/25

Jefferies Keeps Their Buy Rating on Alkermes (ALKS)

David Hoang

Deutsche Bank

$55→$45

Buy

55.71%

Upside

Reiterated

11/13/25

Alkermes (ALKS) Gets a Buy from Deutsche Bank

Benjamin Burnett

Wells Fargo

$42→$37

Buy

28.03%

Upside

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Alkermes (NASDAQ: ALKS)

Jason Gerberry

Bank of America Securities

$34

Hold

17.65%

Upside

Reiterated

11/12/25

Alkermes: Hold Rating Amid Mixed Trial Results and Uncertain Market PositionWe don’t see clear winner in the orexin space yet – competitor’s ORX-750 Ph2a data in NT2 were limited to 2-weeks, vs ALKS noting tachyphylaxis was more apparent before week-4 in Vibrance-2. Ph2 IH data offers an avenue for de-risking, but IH data could be more variable than in NT2. We will also get detailed safety data from Vibrance-2 presentation at a medical conference. We maintain Neutral on ALKS given balanced risk/reward setup. Primary endpoint met, but effect size below expectation We were looking for high-teens placebo-adjusted MWT for clear differentiation vs existing therapies, including ~6-minute placebo-adjusted delta that had been reported for Lumryz in Sleep 2023. That said, we note bulls had been framing 10-minute placebo- adjusted MWT as sufficient for today’s topline.

Ami Fadia

Needham

$44

Buy

52.25%

Upside

Reiterated

11/12/25

Alkermes' Alixorexton Shows Promising Results in NT2 Patients, Justifying Buy Rating

Joseph Thome

TD Cowen

$40

Buy

38.41%

Upside

Reiterated

11/12/25

Analysts Conflicted on These Healthcare Names: Alkermes (NASDAQ: ALKS), Xoma (NASDAQ: XOMA) and Novavax (NASDAQ: NVAX)we continue to see the therapy as a viable option and remain at Buy

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

11/12/25

Alkermes' Strong Position and Misinterpreted Data: Justifying a Buy Rating

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$50

Buy

73.01%

Upside

Initiated

11/10/25

Alkermes (ALKS) Receives a New Rating from Roth MKM

Paul Matteis

Stifel Nicolaus

$36→$42

Buy

45.33%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)We rate ALKS shares Buy.

Uy Ear

Mizuho Securities

$40→$45

Hold

55.71%

Upside

Reiterated

10/29/25

Alkermes (ALKS) Receives a Buy from Mizuho Securitiesraising our PT from $40 to $45 and reiterating our OP.

David Amsellem

Piper Sandler

$38→$45

Buy

55.71%

Upside

Reiterated

10/23/25

Alkermes (ALKS) Gets a Buy from Piper SandlerRaising PT to $45 from $38; We reiterate our Overweight rating

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Douglas Tsao

H.C. Wainwright

$46

Hold

59.17%

Upside

Reiterated

11/20/25

Leonid Timashev

RBC Capital

$47

Buy

62.63%

Upside

Reiterated

11/19/25

Analysts Are Bullish on These Healthcare Stocks: Alkermes (ALKS), Medtronic (MDT)

Joon Lee

Truist Financial

$50→$55

Buy

90.31%

Upside

Reiterated

11/17/25

Truist Financial Keeps Their Buy Rating on Alkermes (ALKS)

Akash Tewari

Jefferies

$58

Buy

100.69%

Upside

Reiterated

11/13/25

Jefferies Keeps Their Buy Rating on Alkermes (ALKS)

David Hoang

Deutsche Bank

$55→$45

Buy

55.71%

Upside

Reiterated

11/13/25

Alkermes (ALKS) Gets a Buy from Deutsche Bank

Benjamin Burnett

Wells Fargo

$42→$37

Buy

28.03%

Upside

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Alkermes (NASDAQ: ALKS)

Jason Gerberry

Bank of America Securities

$34

Hold

17.65%

Upside

Reiterated

11/12/25

Ami Fadia

Needham

$44

Buy

52.25%

Upside

Reiterated

11/12/25

Alkermes' Alixorexton Shows Promising Results in NT2 Patients, Justifying Buy Rating

Joseph Thome

TD Cowen

$40

Buy

38.41%

Upside

Reiterated

11/12/25

Analysts Conflicted on These Healthcare Names: Alkermes (NASDAQ: ALKS), Xoma (NASDAQ: XOMA) and Novavax (NASDAQ: NVAX)we continue to see the therapy as a viable option and remain at Buy

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

11/12/25

Alkermes' Strong Position and Misinterpreted Data: Justifying a Buy Rating

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$50

Buy

73.01%

Upside

Initiated

11/10/25

Alkermes (ALKS) Receives a New Rating from Roth MKM

Paul Matteis

Stifel Nicolaus

$36→$42

Buy

45.33%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)We rate ALKS shares Buy.

Uy Ear

Mizuho Securities

$40→$45

Hold

55.71%

Upside

Reiterated

10/29/25

Alkermes (ALKS) Receives a Buy from Mizuho Securitiesraising our PT from $40 to $45 and reiterating our OP.

David Amsellem

Piper Sandler

$38→$45

Buy

55.71%

Upside

Reiterated

10/23/25

Alkermes (ALKS) Gets a Buy from Piper SandlerRaising PT to $45 from $38; We reiterate our Overweight rating

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

1 Month

xxx

Success Rate

11/19 ratings generated profit

Average Return

+3.61%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.89% of your transactions generating a profit, with an average return of +3.61% per trade.

3 Months

xxx

Success Rate

13/19 ratings generated profit

Average Return

+5.41%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.42% of your transactions generating a profit, with an average return of +5.41% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

12/19 ratings generated profit

Average Return

+16.37%

reiterated a buy rating 28 days ago

Copying Paul Matteis's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +16.37% per trade.

2 Years

xxx

Success Rate

16/22 ratings generated profit

Average Return

+9.04%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 72.73% of your transactions generating a profit, with an average return of +9.04% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALKS has received 37 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. ALKS average Analyst price target in the past 3 months is 44.50.

Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is $0.42 with a range of $0.29 to $0.50. The previous quarter’s EPS was $0.68. ALKS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $378.08M with a range of $357.00M to $400.84M. The previous quarter’s sales results were $394.19M. ALKS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?

Based on analyst ratings, Alkermes plc’s 12-month average price target is 44.50.

What is ALKS’s upside potential, based on the analysts’ average price target?

Alkermes plc has 53.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALKS a Buy, Sell or Hold?

Alkermes plc has a consensus rating of Moderate Buy which is based on 11 buy ratings, 5 hold ratings and 0 sell ratings.

What is Alkermes plc’s price target?

The average price target for Alkermes plc is 44.50. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $58.00 ,the lowest forecast is $34.00. The average price target represents 53.98% Increase from the current price of $28.9.

What do analysts say about Alkermes plc?

Alkermes plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of ALKS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alkermes (ALKS) Stock Forecast & Price Target

ALKS Analyst Ratings

ALKS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alkermes

ALKS Analyst Recommendation Trends

ALKS Financial Forecast

ALKS Earnings Forecast

ALKS Sales Forecast

ALKS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts